JPMorgan analysts have unveiled their August list of top stock picks, featuring key recommendations like growth-oriented Walmart and pharmaceutical giant Eli Lilly, amidst a volatile market landscape in July. Despite refraining from adding new stocks, the firm removed two energy providers, emphasizing opportunities in companies leveraging AI for delivery networks and strong drug sales like Mounjaro, which boosted Eli Lilly’s performance.
As August commences a fresh trading month, JPMorgan's team of analysts has released its highly anticipated updated list of top stock ideas. July proved to be a challenging period for the stock market, navigating through volatile oil prices exacerbated by the Iran war, alongside a mix of robust second-quarter corporate profit reports. The Federal Reserve, under the leadership of new Chairman Kevin Warsh, opted to keep benchmark lending rates stable, even as Warsh reiterated his commitment to curbing inflation. Despite these significant events, the S&P 500 and Dow Jones Industrial Average concluded the month with only marginal changes. However, JPMorgan identifies numerous stocks with substantial potential for upside.
Each month, JPMorgan's analysts diligently compile their premier investment recommendations, categorizing them across key themes: growth, income, value, and short ideas. For August, the team decided against introducing any new stocks to their top picks, instead removing two energy sector providers from their roster.
Among the featured selections on JPMorgan's list, Walmart (WMT) stands out as a growth-oriented consumer stock. The Bentonville, Arkansas-based retailer has seen its shares decline by 16% over the last three months, following a less-than-favorable fiscal year outlook released alongside its first-quarter earnings in May. Yet, Mizuho analysts echo JPMorgan's positive sentiment, selecting Walmart as a top pick in late July and reaffirming an "overweight" investment rating. They particularly commend advancements in Walmart's delivery network as a significant growth driver.
Analyst David Bellinger commented on Walmart's innovative approach: "We undertook an extensive analysis of Walmart's (WMT) ultra-fast delivery network — relying heavily on AI to stress-test delivery times, identify pockets of opportunity and quantify the number of dark stores needed to facilitate 30-minute nationwide delivery." Bellinger further emphasized, "Our findings indicate WMT's network design is still underappreciated, and developing into an increasingly powerful competitive edge/demand consolidator."
Another prominent stock favored by JPMorgan analysts is the drug manufacturer Eli Lilly (LLY). Goldman Sachs corroborated this positive outlook, reiterating a "buy" rating on Lilly in a July 24 note to clients, anticipating the Indianapolis-based drugmaker's second-quarter earnings report. Earlier in the year, Eli Lilly's shares faced headwinds due to its new oral weight-loss pill, Foundayo, reportedly underperforming compared to competing products. Nevertheless, the stock has since staged an impressive recovery, buoyed by strong first-quarter results that surpassed analyst estimates, largely attributed to robust Mounjaro sales.
Goldman analyst Asad Haider remarked, "LLY shares have rallied +39% since the company's 1Q26 print, which featured an impressive beat/raise driven by [outside the United States] Mounjaro and marked a turning point that served to shift the narrative toward the strength across the entire incretin franchise." Haider also noted, "Heading into 2Q26 earnings (Aug 5th), we anticipate the same themes will remain in focus, albeit on a more solid foundation given updates over the past 2 months have further boosted confidence on the company's rapidly evolving next-gen obesity engine."
Concluding their monthly adjustments, JPMorgan announced the removal of Cheniere Energy and Targa Resources from their curated collection of stock recommendations.
